1242087-97-3

Upstream product

• 1303533-76-7 2,2-dibromo-1-(6-bromonaphthalen-2-yl)ethanone 
• 50637-83-7 2-bromo-1-(6-bromonaphthalen-2-yl)ethanone 
• 861880-64-0 6-bromo-N-methoxy-N-methyl-2-naphthamide 
• 1228551-96-9 (S)-tert-butyl 2-(5-(6-bromonaphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 1590-25-6 1-(6-bromonaphthalen-2-yl)ethanone 
• 1031747-50-8 2-(6-bromo-1H-benzoimidazol-2-yl)pyrrolidine-1-carboxylic acid benzyl ester 
• 1228552-26-8 (S)-tert-butyl 2-(5-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 580-13-2 2-bromonaphthalene 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 1031747-50-8 (S)-2-(5-bromo-1H-benzoimidazol-2-yl)pyrrolidine-1-carboxylic acid benzyl ester 
• 1031747-33-7 (S)-2-[5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-benzoimidazol-2-yl]pyrrolidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R' are, each independently,-CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.